We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+27.74%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.71B
AUM Growth
+$107M
Cap. Flow
-$182M
Cap. Flow %
-10.62%
Top 10 Hldgs %
37.71%
Holding
102
New
9
Increased
24
Reduced
36
Closed
9

Top Buys

Rank Stock Value
1
HTFL
Heartflow Inc
HTFL
+$8.04M
2
CDTX
Cidara Therapeutics
CDTX
+$7.36M
3
LENZ
LENZ Therapeutics
LENZ
+$5.6M
4
TVTX icon
Travere Therapeutics
TVTX
+$4.82M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.15M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$30.4M
2
BPMC
Blueprint Medicines
BPMC
+$23.8M
3
ARGX icon
argenx
ARGX
+$21.8M
4
INSM icon
Insmed
INSM
+$17.2M
5
UNH icon
UnitedHealth
UNH
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
51
DELISTED
Soleno Therapeutics
SLNO
$10.4M 0.61%
154,528
– –
DYN icon
52
Dyne Therapeutics
DYN
$4.95B
$10.4M 0.61%
824,061
+243,063
+42% +$2.77M
MREO
53
Mereo BioPharma
MREO
$43.5M
$9.42M 0.55%
4,570,649
+105,357
+2% +$194K
ACRS icon
54
Aclaris Therapeutics
ACRS
$868M
$8.76M 0.51%
4,609,309
-160,000
-3% -$279K
GOSS icon
55
Gossamer Bio
GOSS
$86.1M
$8.59M 0.5%
3,266,960
– –
HTFL
56
Heartflow Inc
HTFL
$2.53B
$8.41M 0.49%
+250,000
New +$8.04M
INSP icon
57
Inspire Medical Systems
INSP
$1.73B
$8.2M 0.48%
110,500
+3,000
+3% +$304K
AGL icon
58
Agilon Health
AGL
$1.63B
$7.18M 0.42%
278,652
+16,636
+6% +$628K
EW icon
59
Edwards Lifesciences
EW
$53B
$6.84M 0.4%
88,000
-43,000
-33% -$3.36M
AMLX icon
60
Amylyx Pharmaceuticals
AMLX
$2.53B
$6.79M 0.4%
499,764
– –
REGN icon
61
Regeneron Pharmaceuticals
REGN
$83.2B
$6.35M 0.37%
11,300
– –
BCAX
62
Bicara Therapeutics
BCAX
$1.82B
$5.85M 0.34%
370,666
+34,596
+10% +$387K
JANX icon
63
Janux Therapeutics
JANX
$1B
$5.14M 0.3%
210,366
+100
+0% +$2.44K
MBX
64
MBX Biosciences
MBX
$3.19B
$4.95M 0.29%
+282,624
New +$3.78M
TMO icon
65
Thermo Fisher Scientific
TMO
$222B
$4.85M 0.28%
10,000
– –
BBIO icon
66
BridgeBio Pharma
BBIO
$16.6B
$4.41M 0.26%
+85,000
New +$4.15M
ATEC icon
67
Alphatec Holdings
ATEC
$1.47B
$4.4M 0.26%
302,500
+35,000
+13% +$487K
ACHC icon
68
Acadia Healthcare
ACHC
$2.96B
$4.21M 0.25%
170,000
-526,000
-76% -$11.7M
OCUL icon
69
Ocular Therapeutix
OCUL
$2.03B
$3.51M 0.2%
+300,000
New +$3.59M
TLPH icon
70
Talphera
TLPH
$73.2M
$3.21M 0.19%
3,589,186
+3,272,726
+1,034% +$1.9M
ALKS icon
71
Alkermes
ALKS
$8.29B
$3.2M 0.19%
+106,537
New +$3M
SION
72
Sionna Therapeutics
SION
$203M
$2.92M 0.17%
99,429
– –
FOCL
73
EDAP TMS S.A.
FOCL
$228M
$2.91M 0.17%
1,270,000
– –
JSPR icon
74
Jasper Therapeutics
JSPR
$26.6M
$2.62M 0.15%
1,100,726
+555,555
+102% +$1.68M
WST icon
75
West Pharmaceutical
WST
$24.8B
$2.56M 0.15%
9,750
-41,280
-81% -$10M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Rock Springs Capital Management held 102 positions worth $1.71B, up 6.7% from $1.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Rock Springs Capital Management withdrew a net $182M in Q3 2025, closing 9 positions and reducing 36 holdings. Its most notable exit was Blueprint Medicines, an estimated $23.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

Against the trend, Rock Springs Capital Management opened a new position in Heartflow Inc worth $8.41M.

  • Rock Springs Capital Management's largest Q3 2025 buy was Heartflow Inc: 250,000 shares worth $8.41M.
  • Rock Springs Capital Management added most to Cidara Therapeutics in Q3 2025, an estimated $7.36M increase.
  • Rock Springs Capital Management's biggest Q3 2025 reduction was Merus, cutting an estimated $30.4M.
  • Rock Springs Capital Management fully exited Blueprint Medicines in Q3 2025, selling an estimated $23.8M.
  • Rock Springs Capital Management's ten largest holdings make up 38% of its $1.71B portfolio in Q3 2025.
  • Rock Springs Capital Management opened 9 new positions and closed 9 in Q3 2025.
  • Rock Springs Capital Management's portfolio value rose 6.7% quarter-over-quarter to $1.71B.

Based on Rock Springs Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.